72results about How to "Inhibit bone resorption" patented technology

The invention relates to a medical degradable and absorbable Mg-Sr system magnesium alloy implant and a preparation method thereof. The medical implant is made of Mg-Sr system alloy, and the Mg-Sr system alloy comprises the following elements in percentage by weight: 0 to 5 percent of strontium (except for 0 percent), a small amount of trace elements, namely one or more of manganese, zirconium, stannum, rare earth and yttrium and the balance of magnesium, wherein the total content of the trace elements is less than 3 percent. In-vivo and in-vitro experiments prove that the Mg-Sr system magnesium alloy implant does not have toxicity, has high histocompatibility, and is a reliable biological medical implant material.

The invention discloses high-purity mangiferin prepared from leaves and twigs of aquilaria sinensis and a preparation method thereof. The method comprises the following steps: on the basis of utilizing leaves and/or twigs of aquilaria sinensis as raw materials, extracting with an alcohol solution; after recovering alcohol at reduced pressure, carrying out water precipitation, alcohol precipitation, devitrification and the like so as to obtain a mangiferin crude product; and then recrystallizing to prepare the high-purity mangiferin. The method has the advantages that the leaves and twigs of aquilaria sinensis are used as the raw materials; the content of the mangiferin is high, and the variety and quantity of impurities are both low; the obtained high-purity mangiferin dose not contain allergic components, and the final product is high in quality and can be widely applied to the industries such as medicine, health care products and cosmetics; and the method has the advantages of simple, stable, practicable preparation process step, short production period, less labor consumption and low cost.

The invention provides an artificial joint with a micro-nano graded topological surface structure and a preparation method of the artificial joint. The artificial joint is formed by compounding a titanium alloy substrate, a micro-porous titanium dioxide surface layer prepared by a micro-arc oxidization method, and a zinc oxide nano rod or a nano taper deposited and grown on the hole wall of the surface, namely the micro-porous titanium dioxide biological activity surface layer is obtained on the surface of an artificial joint titanium substrate through the micro-arc oxidization method; and furthermore, electric depositing parameters are adjusted and a zinc oxide nano rod/taper is deposited and prepared on the titanium dioxide biological activity surface layer, so as to form the artificial joint with the micro-nano graded topological surface structure. The artificial joint can utilize abundant titanium dioxide micron hole structures on the surface and a zinc oxide nano topological structure deposited and grown in the hole wall to enhance the biological effects of adhesion, growth, multiplication and the like of surface osteoblast, and realize the slow release of the element zinc; and therefore, the antibacterial capability, the biological activity, the biocompatibility and the cell regulating and controlling capability of the surface at an implantation initial stage are greatly improved.

The present invention discloses one kind of medicine for treating osteoporosis and its preparation process. The medicine is developed based on the Chinese medicine theory of benefiting liver and kidney to strengthen bones and muscles, and is prepared with seven kinds of Chinese medicinal materials, including malaytea scurfpea fruit, epimedium, wolfberry fruit, privet fruit, drynaria rhizome, cibot rhizome and cyathula root and proper amount of supplementary material. The medicine has the functions of invigorating liver and kidney, strengthening bone and relieving pain, and possesses obvious curative effect on osteoporosis and no side effect. The medicine may be prepared into different preparation forms for different clinical requirements.

The invention provides application of evodiamine in preparation of an anti-osteoporosis drug and the anti-osteoporosis drug and relates to the technical field of biological medicine. The evodiamine can inhibit activation of protein kinase in an RANKL-induced osteoclast differentiation and maturation RANKL-ERK-NFAT signal channel in effective dose, further bone phagocytosis capability of RANKL-induced osteoclast is inhibited, expression of osteoclast differentiation specific genes such as c-Fos and NFATc1 is obviously reduced, bone absorption is inhibited, bone formation is promoted, and finally the effect of preventing osteoporosis is achieved. The application of the evodiamine in preparation of the anti-osteoporosis drug has the characteristics of definite curative effect and small side effect, and the problem that an existing medicine used for treating bone loss disease has serious adverse reaction in clinical application is relieved.

The present invention discloses the novel use of bone-care medicament, wherein banana tree root, creeping oxalis, psoralea fruit and dipsacus root are used as raw material, conventional processes are employed to obtain various extracts, auxiliary materials are charged to produce dosage forms of oral administration and injection suitable for clinical applications. The medicament can be used for treating osteoarthritis and osteoporosis.

The invention discloses Zn-HA series zinc alloy, and a preparation method and application thereof. The zinc alloy provided by the invention comprises Zn and HA, wherein the mass percentage of the HA in the zinc alloy is 0 to 10 percent, but does not include 0. The zinc alloy also comprises trace elements, wherein the trace elements are at least one of silicon, phosphorus, lithium, silver, tin and rare earth element; and the mass percentage of the trace elements is 0 to 3 percent, but does not include 0. The Zn-HA series zinc alloy provided by the invention has the mechanical properties according with the requirements of a medical implant material on strength and toughness, does not have cytotoxicity on endothelial cells and osteoblasts, can inhibit proliferation of smooth muscle cells and has good histocompatibility and blood compatibility; meanwhile, the Zn-HA series zinc alloy can be regulated, controlled and degraded by body fluid and the dissolved metal ions can be absorbed and utilized by a living body or can be metabolized and discharged out of the body; and the Zn-HA series zinc alloy also has excellent antibacterial property and can be applied to preparation of medical implants.

The present invention discloses bone density increasing health-care soft capsules. Content components comprise calcium carbonate, vitamin D3, a soybean extract, soybean oil, beeswax and soybean phospholipids. Capsule skin components are as follows: gelatin, glycerol, purified water, titanium dioxide, caramel color and capsanthin. Preparation method is as follows: capsule preparing: firstly, the glycerol and purified water are threw into a capsule melting tank, the gelatin is threw, water is added into the titanium dioxide, caramel color and capsanthin, and capsule liquid mixed materials are obtained; the capsule liquid mixed materials are then vacuumed, the vacuumed materials are filtered, and a capsule liquid is put still for standby applications; content preparing: firstly the vitamin D3 and soybean oil are stirred evenly, then a small amount of the soybean oil is added, and the materials are stirred and mixed evenly to obtain vitamin D3 mixed oil for standby applications; the remaining soybean oil and beeswax are placed in a material blending tank to obtain an oil and beeswax mixture; then the vitamin D3 mixed oil and soybean lecithin are successively added into the oil and beeswax mixture, and then the soybean extract and calcium carbonate are added to obtain total mixed materials; and the total mixed materials are threw into a homogenizer to be homogenized and emulsified to obtain the contents of the soft capsules for standby applications.

The invention provides a degradable antibacterial magnesium alloy and a preparation method of the degradable antibacterial magnesium alloy, and relates to the field of metal biomedical materials. Thedegradable antibacterial magnesium alloy comprises main active elements of Ag, Cu, Zn and Sr, and by means of composition optimization design of the magnesium alloy, the components comprise, by mass,1.35-1.65% of Ag, 0.9-1.1% of Cu, 3.6-4.4% of Zn, 0.9-1.1% of Sr, 0.36-0.44% of Ca and the balance Mg and other inevitable impurities. After the magnesium alloy material implant finishes the action, the magnesium alloy material implant can be completely degraded to avoid secondary operation removal, the medical cost and the pain of patients are reduced, the antibacterial property of the implant isimproved, and the magnesium alloy material implant has the functions of promoting osteoblast formation and inhibiting osteoclast bone absorption; the degradable antibacterial magnesium alloy adopts asemi-solid rheological die casting process, the microstructure of the product is uniformly distributed, the internal structure is compact, the defects of pores, segregation and the like are few, andthe requirements for high quality and high precision of implant products can be met.

The invention relates to the technical field of medicines, and discloses a preparation method of total iridoid glycoside of ligustrum lucidum ait and application of the total iridoid glycoside of ligustrum lucidum ait to preparation of an anti-osteoporosis medicine. A ligustrum lucidum ait medicinal material is subjected to thermal extraction by using hydrous ethanol to obtain an extracting solution; the extracting solution is purified by adopting macroporous adsorption resin to obtain a total iridoid glycoside extract of the ligustrum lucidum ait. The total iridoid glycoside of the ligustrumlucidum ait contains 19.67 weight percent of specnuezhenide, 0.95 weight percent of oleuropein, 36.44 weight percent of nuezhenoside and 9.01 weight percent of oleonuezhenide. The extract can promoteformation of osteocytes and suppress bone absorption of the osteocytes; under the action of multiple relevant indexes for bone metabolism, the anti-osteoporosis effect is enhanced; the aim of preventing and treating osteoporosis is fulfilled; the total iridoid glycoside of the ligustrum lucidum ait can be used for preparing a medicine for preventing and treating the osteoporosis.

The invention discloses a composition for promoting bone health. The composition comprises the following raw material components in parts by mass: 3-15 parts of cucumber seeds, 3-15 parts of chicken shells, 1-6 parts of human placenta, 1-4 parts of amygdalus pedunculata oil, 0.5-3 parts of eucommia seed oil, 0.3-1 part of hydrolyzed yolk powder and 0.1-1 part of a calcium nutrition enhancer. The composition for promoting bone health prepared by the invention has the obvious effects of enhancing the physique of children and middle-aged and elderly people and changing the sub-health state of children and middle-aged and elderly people, and has a remarkable improvement effect on bone health diseases, even can be comparable with related conventional treatment medicines to a certain extent, andis expected to be developed into a hot market product for improving the bone health diseases.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention discloses application of cordycepin in the preparation of a medicine for preventing and treating osteoporosis. The cordycepin can inhibit the proliferation of osteoclast, the formation of multinuclear mature osteoclast, the bone resorption ability of osteoclast and the expression of osteoclast differentiation gene and can clear reactive oxygen species (ROS) in osteoclast, thus the physiological steady state of bone is stabilized, the bone loss is prevented, the bone density is kept, and a new medicine is provided to the prevention and treatment of osteoporosis.

The invention discloses application of kavain in preparing drug for treating osteoporosis. Impact of kavain on osteoclast differentiation, osteoclast absorption and osteoblast differentiaon is evaluated through tartrate-resistant acid phosphatase dyeing, immunofluorescence, reverse transcription-polymerase chain reaction and immunoblotting analysis. Results show that kavain inhibits RANKL inducedosteoclast by blocking NFAT and MAPK passages mediated by calcium while NF-kB is unaffected; kavain also inhibits bone resorption o osteoclast and has no obvious impact on differentiation and proliferation of osteoblast. In addition, kavain can inhibit formation of osteoclast to bone loss of ovariectomized mice. Data display that osteoclast of kavain which is a natural compound has specific effect, which shows that kavain has potential value in treating osteoporosis diseases.

The invention provides an RGD peptide-epimedium flavone combination synthesized by combining two structural units of RGD peptides and epimedium flavone which have pharmacological activities of different action mechanisms on osseous metabolic diseases, and also provides a synthesis method thereof. The compound of the invention has two receptor combining sites and simultaneously has the capability of combining estrogen receptors of icaritin and the capability of combining integrins alphaVbeta3 of RGD, and the capabilities of combining the two different receptors can produce a synergistic effect to greatly improve the curative activity of the medicament on osteoporosis and osseous metabolic diseases. The synthesis method has the advantages of high yield, high synthesis speed and easy purification of products.

The invention discloses a medicine for treating osteoporosis and a preparation method thereof. The medicine comprises the following components in parts by weight: 5-10 parts of rhizoma cibotii, 5-10 parts of teasel root, 5-10 parts of gentiana macrophylla, 5-10 parts of notopterygium root, 3-8 parts of peach kernel, 3-8 parts of safflower, 3-8 parts of angelica sinensis, 3-8 parts of ligusticum wallichii, 3-8 parts of myrrh, 3-10 parts of trogopterus dung, 3-10 parts of rhizoma cyperi, 3-10 parts of radix achyranthis bidentatae, 4-6 parts of earthworm, 3-6 parts of liquorice, 5-10 parts of fructus cnidii and 5-10 parts of herba epimedii. The medicine can effectively solve the problem that an existing medicine formula is poor in treatment effect.

The present invention discloses a calcium-phosphorus mixture and its application. Its composition is formed from (by wt%) 1.2%-2.2% of calcium and 0.4%-0.67% of phosphorus. Said calcium-phosphorus mixture can be used for preparing food, health-care product or medicine for inhibiting bone absorption, promoting bone formation and curing bone metabolic abnormality due to PTH deficiency.

The invention relates to a health food for increasing bone density and a preparation method of the health food. The health food is prepared from calcium carbonate, D-glucosamine potassium sulfate, sodium chondroitin sulfate, a rhizoma drynariae extract, a herba epimedii extract and vitamin K2 as main raw materials and auxiliary materials for the health food. The health food directly supplements calcium, inhibits osteoclast activity, promotes bone cell proliferation, repairs damaged cartilage tissues, and nourishes the kidney and bones, so that the health function of increasing bone density is fulfilled.

The invention discloses a preparation method of a medical pure magnesium surface electrophoretic deposition carried bone growth inducing traditional Chinese medicine coating, and relates to a preparation method of a medical pure magnesium surface coating, in order to solve the technical problems that the existing medical magnesium and magnesium alloy materials are too high in degradation rates and cause inflammatory reaction. The preparation method comprises the following steps: one, pure magnesium specimen surface pretreatment is carried out; two, a micro-arc oxidation electrolytic solution is prepared; three, ultrasound micro-arc oxidation treatment is carried out; and four, post treatment is carried out. According to the preparation method, after magnesium and magnesium alloy ultrasound micro-arc oxidation is carried out, electrophoretic deposition is carried out on a hydrophilic and hydrophobic carried purified traditional Chinese medicine coating, after assembly, the matching between a degradation rate and an osseous tissue regenerating or fracture healing rate in vivo is achieved, the surface carried purified traditional Chinese medicine coating has antibacterial and antiphlogistic properties and bone tissue regeneration inducing property; the influencing mechanism of hydrophilic and hydrophobic medicine carrying surfaces on the antibacterial property, the corrosion resistance and the degradation property of the traditional Chinese medicine coating is provided; and a magnesium bone internal fixation material has good mechanical properties of a metallic material, and has corrosion resistance, antibacterial property and excellent bioactivity.

The invention relates to application of vanillin in preparation of drugs for treating/preventing bone matabolic diseases. The vanillin is used for inhibiting the propagation of osteoclasts, the formation of polynuclear mature osteoclasts and the bone crushing capability of the osteoclasts, promoting the apoptosis of mature osteoclasts and regulating and controlling differentiation, fusion and maturing genes and apoptosis related genes of the osteoclasts and has the effects of maintaining a bone stable state, preventing bone loss and maintaining bone density, and novel drugs are provide for treating/preventing osteoclast activity induced diseases.

The invention discloses a traditional Chinese medicine composition for treating osteoporosis, which is prepared from the following traditional Chinese medicine materials in parts by weight: 8-12 parts of spina date seed, 8-12 parts of rhizoma atractylodis, 8-12 parts of rhizoma anemarrhenae, 10-15 parts of burdock, 10-15 parts of the bark of eucommia, 10-15 parts of cortex lycii radicis, 15-20 parts of folium artemisiae argyi, 15-20 parts of dandelion, 15-20 parts of caulis spatholobi, and 15-20 parts of the root of bidentate achyranthes. The traditional Chinese medicine composition disclosed by the invention is not only capable of inhibiting bone resorption but also capable of stimulating stone formation; simultaneously, the treatment cost is low; and the patient dependency is high.

The invention belongs to the field of health products and in particular relates to a pharmaceutical composition for increasing bone density and a preparation method thereof. The pharmaceutical composition provided by the invention is prepared from the following raw materials in parts by weight: 2-6 parts of oysters, 0.5-2 parts of malt, 1-4 parts of Chinese yams, 1-3 parts of poria cocos, 1-4 parts of Chinese dates, 0.5-2 parts of liquorice, 0.5-2 parts of endothelium corneum gigeriae, 0.000001-0.000005 part of vitamin D2, 5-15 parts of calcium gluconate, 2-5 parts of sodium L-ascorbic-acid-2-phosphate, 1-4 parts of glutathione, 1-4 parts of phellinus igniarius fermented powder and 2-75 parts of auxiliary materials. The pharmaceutical composition provided by the invention has a good calcium supplementing effect, is rich in nutritional ingredients, safe and effective, convenient to take and applicable to being taken by children for a long time and can promote sustainable growth of the bone density.

The invention provides application of magnesium hydride in preparation of a composition for preventing and treating chronic periodontitis, and magnesium hydride toothpaste. The weight percentage of magnesium hydride in the composition or the magnesium hydride toothpaste is 1-3%. The toothpaste has the effects of sterilizing, resisting inflammation, resisting oxidation, removing tooth stains, improving breath or halitosis, relieving redness, swelling and bleeding of gingiva and gingival recession, and improving periodontitis symptoms. The invention also discloses application of magnesium hydride in preparation of a composition for preventing and treating chronic periodontitis. According to the invention, a proper amount of magnesium hydride fine particles are added into the toothpaste body;and the magnesium hydride particles can be hydrolyzed into hydrogen and magnesium ions with an anti-inflammatory effect, and also can inhibit alveolar bone absorption. The composition containing magnesium hydride is safe to use, and can effectively prevent the occurrence and development of periodontal diseases after long-term use.

The invention relates to a drug for treatment of osteoporosis, wherein the drug consists of oysters, premna fulva craib, dracaena cochinchinensis, soft-shelled turtle, herba lespedezae cuneatae, davallia formosana, tuber dioscoreae persimilis, membranaceous beautyleaf root, fennel and a pearl powder. The drug has the effect for relief and treatment of osteoporosis, and has the advantages of low price, and no toxic or side effects, and is safe and reliable.